Edition:
United States

Hansa Medical AB (HMED.ST)

HMED.ST on Stockholm Stock Exchange

234.00SEK
23 Feb 2018
Change (% chg)

-2.20kr (-0.93%)
Prev Close
236.20kr
Open
235.00kr
Day's High
239.00kr
Day's Low
232.80kr
Volume
114,315
Avg. Vol
160,581
52-wk High
290.00kr
52-wk Low
96.75kr

Latest Key Developments (Source: Significant Developments)

Hansa Medical Granted Orphan Drug Designation By FDA
Friday, 16 Feb 2018 03:45am EST 

Feb 16 (Reuters) - HANSA MEDICAL AB ::HANSA MEDICAL RECEIVES FDA ORPHAN DRUG DESIGNATION FOR IDES AND THE TREATMENT OF GUILLAIN-BARRÉ SYNDROME.  Full Article

Hansa Medical AB Q4 Net Revenue Sek 1.0 ‍​ Million Versus Sek 0.5 Million Year Ago
Wednesday, 14 Feb 2018 02:00am EST 

Feb 14 (Reuters) - HANSA MEDICAL AB ::Q4 NET REVENUE SEK 1.0 ‍​ MILLION VERSUS SEK 0.5 MILLION YEAR AGO.Q4 OPERATING LOSS SEK ‍​ 48.9 MILLION VERSUS LOSS SEK 33.6 MILLION YEAR AGO.  Full Article

‍Hansa Medical Contemplates Directed Share Issue To Raise About Sek 545 mln​
Wednesday, 29 Nov 2017 11:30am EST 

Nov 29 (Reuters) - Hansa Medical Ab ::‍HANSA MEDICAL CONTEMPLATES A DIRECTED SHARE ISSUE TO RAISE APPROXIMATELY SEK 545 MILLION​.HANSA MEDICAL -COMMISSIONED EVERCORE, RBC CAPITAL AND SEB, TO INVESTIGATE POSSIBILITY OF UNDERTAKING NEW ISSUE OF SHARES TO INSTITUTIONAL INVESTORS.‍INTENDS TO USE PROCEEDS FROM DIRECTED ISSUE TO FUND CONTINUED DEVELOPMENT OF COMPANY'S EXISTING PORTFOLIO​.  Full Article

Hansa Medical Q3 operating loss up at SEK ‍​37.4 mln
Tuesday, 14 Nov 2017 02:00am EST 

Nov 14 (Reuters) - HANSA MEDICAL AB ::Q3 OPERATING LOSS SEK ‍​37.4 MILLION VERSUS LOSS SEK 27.0 MILLION YEAR AGO.Q3 NET REVENUE SEK ‍​678,000 VERSUS SEK 0.9 MILLION YEAR AGO.  Full Article

Hansa Medical: sudden death of CEO Göran Arvidson​
Wednesday, 8 Nov 2017 02:00am EST 

Nov 8 (Reuters) - HANSA MEDICAL AB :‍ANNOUNCES SUDDEN DEATH OF CEO GÖRAN ARVIDSON​.‍CHAIRMAN ULF WIINBERG WILL SERVE AS ACTING CEO.‍BIRGIT STATTIN NORINDER WILL TAKE OVER ROLE AS CHAIRMAN OF BOARD UNTIL FURTHER NOTICE​.  Full Article

Hansa Medical Q2 operating loss at SEK 44.9 million
Thursday, 20 Jul 2017 02:00am EDT 

July 20 (Reuters) - HANSA MEDICAL AB :Q2 NET REVENUE SEK 0.7 MILLION VERSUS SEK 0.5 MILLION YEAR AGO.Q2 OPERATING LOSS SEK 44.9 MILLION VERSUS LOSS SEK 30.7 MILLION YEAR AGO.  Full Article

Hansa Medical Q1 net sales rise to sek 1.1 million
Wednesday, 26 Apr 2017 02:00am EDT 

April 26 (Reuters) - HANSA MEDICAL AB ::Q1 NET SALES SEK 1.1 MILLION VERSUS SEK 0.6 MILLION YEAR AGO.Q1 OPERATING LOSS SEK 44.8 MILLION VERSUS LOSS SEK 19.9 MILLION YEAR AGO.  Full Article

Hansa Medical appoints Sam Agus as new Chief Medical Officer
Friday, 31 Mar 2017 02:00am EDT 

HANSA MEDICAL AB :HANSA MEDICAL APPOINTS SAM AGUS AS NEW CHIEF MEDICAL OFFICER.  Full Article

Hansa Medical Q4 operating loss widens to SEK 33.6 million
Wednesday, 15 Feb 2017 02:00am EST 

Hansa Medical AB : Q4 net revenue 543,000 Swedish crowns ($60,826) versus 1.2 million crowns year ago .Q4 operating loss 33.6 million crowns versus loss 19.1 million crowns year ago.  Full Article

Hansa Medical discontinues Phase II study in acquired TTP
Wednesday, 21 Dec 2016 03:40am EST 

Hansa Medical AB : Discontinues its Phase II study in acquired Thrombotic Thrombocytopenic Purpura (TTP) . Decision follows it's review of initial results from study demonstrating a non-favourable risk benefit profile . This decision to discontinue study has no impact on Hansa Medical's ongoing studies with IdeS in renal transplantation or planned studies in other autoimmune indications .Efficient cleaving of anti-ADAMTS13 autoantibodies did not result in a convincing positive effect on activity of ADAMTS13 enzyme.  Full Article

BRIEF-Hansa Medical Granted Orphan Drug Designation By FDA

* HANSA MEDICAL RECEIVES FDA ORPHAN DRUG DESIGNATION FOR IDES AND THE TREATMENT OF GUILLAIN-BARRÉ SYNDROME Source text for Eikon: Further company coverage: (Gdynia Newsroom)